

Cortellis Generic Intelligence

医薬品関連の契約情報を収集する

ディール情報コンテンツは契約締結、買収候補先やパートナー提携先の探索、競合企業の調査等に必要の情報を提供します。

検索事例:エムトリシタビンに関する契約情報の収集

1. クイックサーチからエムトリシタビンの製品レコードを検索

emtrid

Products

- emtricitabine
- emtricitabine; tenofovir
- emtricitabine; tenofovir alafenamide
- emtricitabine; tenofovir disoproxil succinate
- emtricitabine; tenofovir disoproxil phosphate
- emtricitabine; tenofovir disoproxil fumarate

2. 製品レコードのディールタブをクリックすると、ディールごとに関連する企業やディールの効力を発揮する国/地域、ディールのステータスやバリュー（情報が付与されたディールに限る）といった情報を明確に確認できます。

emtricitabine

Alert

Product Key Insights
API Manufacturers
Regulatory Filings
Approvals
Launches & Pack Prices
Constraint Date Forecast & Exclusivities
Patents & SPCs
US Patent Challenges
Deals
Competitive Insights
R&D
Scientific

Deals

Customize Columns

Hide All / Show All
Principal Company
Country/Territory
Principal Corporate Group
Partner Company
Country/Territory
Partner Corporate Group
Agreement Type
Status
Value (\$M)
Deal Start Date

表示するコラムをカスタマイズ可能です

各列の表示項目をクリックすることでレコードのソートが可能です

		PARTNER COMPANY	COUNTRY/ TERRITORY	AGREEMENT TYPE	STATUS	VALUE (\$M)	DEAL START DATE	INVOLVED PRODUCTS	SYNOPSIS
		Triangle Pharmaceuticals Inc	US	Drug - Manufacturing/Supply	Active	7.012	30-Jul-2002	emtricitabine lopinavir ***	View
		Gilead Sciences Inc	US	Drug - Development/Commerci...	Active	50	22-Mar-2005	cobicistat elvitegravir ***	View
		Janssen R&D (Ireland)	Ireland	Drug - Development/Commerci...	Active	200	16-Jul-2009	emtricitabine lamivudine ***	View
		Royalty Pharma	US	Drug - Asset Divestment	Active	365	18-Jul-2005	emtricitabine	View
		Gilead Sciences Inc	US	Drug - Development/Commerci...	Active	525	31-Dec-1996	emtricitabine	View
Gilead Sciences Inc	US	Japan Tobacco Inc	Japan	Drug - Commercialization License	Terminated	559	31-Jul-2003	cobicistat elvitegravir ***	View
Emory University	US	Gilead Sciences Inc	US	Drug - Asset Divestment	Active	692	18-Jul-2005	emtricitabine	View

3. デールタイトルをクリックするとデール情報の詳細を確認できます。

DEAL TITLE ↑

Mylan to conduct a phase I clinical study of generic version of ViiV Healthcare's Triumeq for HIV-1 infection

↓

Deal Details

Details and Information

Deal Title

Mylan to conduct a phase I clinical study of generic version of ViiV Healthcare's Triumeq for HIV-1 infection

More Information

Cortellis Competitive Intelligence

Status

Active

Principal Company

ViiV Healthcare Ltd

Principal Country/Territory

UK

Partner Company

Mylan Inc, US

Partner Country/Territory

US

Deal Start Date

01-Sep-2021

Deal End Date

No data

Agreement Type

Drug - Early Research/Development

Value (\$M)

No data

Involved Products

abacavir

dolutegravir

lamivudine

Events

01-Sep-2021

- In September 2021, Mylan had entered into a phase I clinical study of generic version of ViiV Healthcare's Triumeq for the treatment of HIV-1 infection.- Triumeq is a phase I, fixed-dose single-pill combination of the integrase inhibitor of dolutegravir and the dual nucleoside reverse transcriptase inhibitor and the dual nucleoside reverse transcriptase inhibitor Epzicom for the treatment of HIV-1 infection.- Financials were not disclosed.

Sources

"NCT05030025 : Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/3 mg/30 mg)", www.clinicaltrials.gov, Issue: September 01, 2021

4.【製品に関するお問い合わせ】 クラリベイト カスタマーケア
(ts.support.jp@clarivate.com)